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Abstract 
To further elucidate the mechanisms for short-term regulation of the receptor for insulin-like growth factor II (IGF-II), we investigated 
effects of insulin, cAMP and phosphatase inhibitors on cell surface ~25I-IGF-II binding in rat adipocytes. Preincubation with the 
serine/threonine phosphatase inhibitor okadaic acid (OA, 1 /zM) or the non-hydrolysable cAMP analogue N6-mbcAMP (4 mM) 
markedly impaired insulin-stimulated 125I-IGF-II binding. Furthermore, addition of OA enhanced the inhibitory effect exerted by 
N6-mbcAMP. N6-mbcAMP also induced an insensitivity to insulin which was normalized by concomitant addition of the tyrosine 
phosphatase inhibitor vanadate (0.5 raM). In contrast, vanadate did not affect the impairment in maximal insulin-stimulated ~esI-IGF-II 
binding produced by either OA or N6-mbcAMP. Phospholipase C (PLC), which cleaves phospholipids at the cell surface, markedly 
enhanced cell surface 125I-IGF-II binding in a concentration-dependent ma ner. Scatchard analysis demonstrated that the effect of PLC 
was due to an increased number of binding sites suggesting that 'cryptic' IGF-II receptors are associated with the plasma membrane 
(PM). PLC (5 U/ml) also reversed the N6-mbcAMP-induced decrease of 125I-IGF-II binding at a low insulin concentration (10/~U/ml). 
Taken together, these data indicate that cAMP, similar to its effects on the glucose transporter GLUT 4 and the insulin receptor, may 
increase the proportion of functionally cryptic IGF-II receptors in the PM through mechanisms involving serine phosphorylation, possibly 
of a docking or coupling protein. Tyrosine phosphorylation appears to exert an opposite ffect promoting the full cell surface expression 
of receptors. 
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1. Introduction 
In basal non-stimulated rat adipocytes, the major pro- 
portion of the receptors for insulin-like growth factor II 
(IGF-II)/mannose-6-phosphate is located in an intra- 
cellular compartment [1]. Upon insulin stimulation, IGF-II 
receptors are translocated from the intracellular low den- 
sity microsomal fraction to the plasma membrane (PM) 
Abbreviations: ADA, adenosine deaminase; BSA, bovine serum albu- 
min; IGF-II, insulin-like growth factor II; MHC-I, major histocompatibil- 
ity complex class I antigen; N6-mbcAMP, N6-monobutyryl cyclic AMP; 
OA, okadaic acid; PIA, N6-(R-phenylisopropyl) adenosine; PLC. phos- 
pholipase C; PM, plasma membrane. 
* Corresponding author. Present address: Department of Medicine, 
Ume~ University Hospital, S-90185, Ume~, Sweden. Fax: +46 90 
137633. 
0005-2736/96/$15.00 © 1996 Elsevier Science B.V. All rights reserved 
PII S0005-2736(96)00037-5  
[1-3]. This stimulatory effect of insulin is similar to its 
action on glucose transporter t anslocation [4,5]. It is rapid 
and concentration-dependent, resulting in an enhancement 
of the number of IGF-II receptors at the cell surface up to 
10- to 20-fold [3,6]. This effect of insulin is blunted in 
insulin-resistant cells, e.g., following cAMP treatment [6]. 
The mechanisms involved may include impaired insulin 
binding as well as signaling resulting in a reduced translo- 
cation of IGF-II receptors [6-9]. 
Detailed work on IGF-II receptor translocation has indi- 
cated that the marked effect of insulin in the intact cell is 
only partially recovered when binding to membranes is 
assessed following cell fractionation [1]. Moreover, a pre- 
vious study from our laboratory demonstrated that, in 
insulin-resistant, cAMP-treated cells, the reduction in in- 
sulin-stimulated IGF-II binding to the cell surface, was not 
so marked when receptor translocation was assessed by 
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IGF-II binding to solubilized PMs [6]. These observations 
indicate that not only the translocation of IGF-II receptors 
to the PM is impaired, but also an additional step, e.g., 
receptor activation or insertion appears to be altered. In the 
present study we therefore directly examined whether evi- 
dence for 'cryptic' IGF-II receptors within the PM in rat 
adipocytes could be obtained by using phospholipase C 
(PLC) under stimulated and non-stimulated conditions. 
The regulatory effects of serine and tyrosine phosphoryla- 
tion events were also explored in experiments with the 
serine and tyrosine phosphatase inhibitors okadaic acid 
(OA) and vanadate, respectively. 
2. Materials and methods 
2.1. Materials 
3-[125I]-Tyr-insulin-like growth factor II (IGF-II; spec. 
act. 263 /xCi/~g) was from Amersham (Amersham, 
Buckinghamshire, UK). Human recombinant IGF-II, 
phopholipase C (type XIV: from C. perfringens), N 6- 
monobutyryl cyclic AMP (N6-mbcAMP), bovine serum 
albumin (BSA; fraction V) and sodium orthovanadate 
(Na3VO 4) were from Sigma Chemical Co. (St. Louis, MO, 
USA). Adenosine deaminase (ADA) and N6-(R-phenyliso - 
propyl) adenosine (PIA) were from Boehringer-Mannheim 
(Mannheim, Germany). Human monocomponent insulin 
was a gift from Novo Nordisk (Copenhagen, Denmark). 
Okadaic acid was from LC Laboratories (Boston, MA, 
USA). Medium 199 was obtained from Gibco BRL, Life 
Technologies (Paisley, UK). A synthetic peptide fragment 
from the major histocompatibility complex class I (MHC-I) 
molecule (DK69-85) was kindly donated by Dr. L. Olsson 
(Receptron, San Francisco, CA, USA). 
2.2. Isolation of adipocytes 
Male Sprague-Dawley rats, weighing 150-200 g and 
fed ad libitum, were stunned and decapitated. The epididy- 
mal fat pads were instantly excised and minced. Fat cells 
were isolated in medium 199 containing 0.6 mg/ml colla- 
genase and 4% BSA at 37°C for 1 h in a shaking water 
bath (~ 120 rpm) as previously described [10]. 
2.3. 125I-IGF-H binding to intact cells 
in the absence or presence of PLC, which cleaves phospho- 
lipids at the cell surface [12]. After the incubation, cells 
and medium were separated by centrifugation through 
dinonyl phtalate and ~25I-IGF-II binding to cells was mea- 
sured. Non-specific binding, defined as binding in the 
presence of 200 ng/ml unlabeled IGF-II, was subtracted. 
2.4. ~251-IGF-H binding to PMs 
Isolated PMs were prepared as described by Weber et 
al. [13]. To obtain similar binding conditions as those in 
intact cells, binding of 125I-IGF-II (0.2 ng/ml) was carried 
out at 24°C for 30 min in medium 199 containing 4% 
BSA, protease inhibitors (leupeptin 2 mg/1, pepstatin 1 
mg/ l  and phenyl methylsulphonylfluoride 25 mg/1) and 
different concentrations of PLC. Then separation of ra- 
dioactivity bound to the PM from free radioactivity was 
achieved by centrifugation through an oil mixture of dioctyl 
phthalate and dibutyl phthalate (2:3) at 12000 × g for 20 
min and I:5I-IGF-II binding to the PM (the pellet) was 
then measured. 
125I-IGF-II binding to receptors from solubilized PM 
was also performed. Solubilized PM was prepared as 
previously described [6]. Briefly, PM samples were solubi- 
lized in medium 199 containing 0.5% Triton X-100 for 60 
min at 4°C in the presence of the protease inhibitors. The 
receptors were precipitated with polyethyleneglycol t - 
gether with IgG. After vigorous vortexing, the samples 
were centrifuged at 11 000 × g for 5 min and the pellets 
were washed. After resuspending the pellets in medium, 
binding of ~25I-IGF-II in the presence or absence of 200 
ng/mi unlabeled IGF-II (non-specific binding) was per- 
formed at 24°C for 30 min. The receptors were again 
precipitated and the pellets extensively washed three times. 
2.5. Statistics 
Statistical significance of differences was tested with 
Student's two-tailed t-test for paired data. Results are 
means + S.E.M. unless otherwise indicated. 
3. Results 
3.1. Effects of N6-mbcAMP, vanadate and OA on 125I-IGF- 
H binding 
After extensive washing, the cells (lipocrit 5-10%) 
were preincubated with 1 U/ml ADA and 0.1 ~M PIA (a 
non-degradable adenosine analogue, to achieve a defined 
adenosine ffect) and other indicated agents at 37°C for 20 
min in a shaking water bath ( ~ 120 rpm). 2 mM KCN was 
then added for another 5 min in order to deplete the cells 
of ATP and stop receptor internalization and recycling 
[1,11]. Subsequently, cell surface binding of 125I-IGF-II 
(0.2 ng/ml) was carried out at 24°C for 30 min or 60 min 
Preincubation with OA (1 p~M) alone increased cell 
surface 125I-IGF-II binding (n = 4, P < 0.001, Fig. 1). 
N6-mbcAMP (4 mM) alone or together with OA (1 /zM) 
had no effect on basal 125I-IGF-II binding. However, both 
OA and N6-mbcAMP decreased the maximal insulin- 
stimulated (1000/zU/ml) 125I-IGF-II binding (n = 4, P < 
0.01 and P<0.001,  respectively). Moreover, OA and 
N6-mbcAMP when added together additionally decreased 
the maximal stimulation by insulin (1000 /~U/ml) of 
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Fig. 1. Effects of insulin, N6-mbeAMP and okadaic acid (OA) on cell 
surface 125I-IGF-II binding. Rat adipocytes were preincubated at 37°C for 
20 rain with or without insulin (1000 /xU/ml), OA (1 #M) and N 6- 
mbcAMP (4 raM) as indicated. Then, cells were treated with 2 mM KCN 
for 5 min at 37°C, and were transferred to 24°C and ~-~sI-IGF-II (0.2 
ng/ml) was added. After 1 h, cell-associated radioactivity was deter- 
mined. Data are means + S.E.M. of 3-6 separate xperiments. ( * * P < 
0.01, ~ * * P < 0.001, compared to no addition or insulin alone). 
125I-IGF-II binding compared with that of N6-mbcAMP 
plus insulin (n = 4, P < 0.05), but this was, however, not 
significantly different from the inhibition exerted by OA 
alone (Fig. 1). 
N6-mbcAMP (4 mM) shifted the dose-response curve 
for insulin-stimulated 12sI-IGF-II binding to the right, 
whereas vanadate (0.5 mM) added together with N 6- 
mbcAMP clearly restored insulin sensitivity to normal 
(Fig. 2). ECs0 for insulin was 14 + 3, 32 + 4 (P  < 0.05) 
and 14 _+ 2 /xU/ml for control cells and cells treated with 
N6-mbcAMP or N6-mbcAMP plus vanadate, respectively 
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Fig. 2. Effects of N6-mbcAMP and vanadate on the dose-response curve 
for insulin-stimulated 1251-IGF-II binding. Cells were treated as described 
in Fig. 1, but with the indicated concentrations of insulin in the presence 
of 4 mM N6-mbeAMP (• ) ,  0.5 mM vanadate plus N6-mbcAMP (A) or 
in the absence of these agents ( • ). Data are means + S.E.M. of 5 separate 
experiments. 
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Fig. 3. Effects of okadaic acid (OA) and vanadate (van) on 1251-IGF-II 
binding. Cells were treated as described in Fig. 1, but with different 
concentrations of insulin, 1 /zM OA and 0.5 mM vanadate as indicated. 
Data are means + S.E.M. of 4 separate xperiments ( * P < 0.05, * * P < 
0.01, compared to addition of insulin alone at the corresponding concen- 
tration). 
(n = 5). In contrast, vanadate did not significantly affect 
the blunted maximal insulin response following N 6- 
mbcAMP treatment (data not shown). Vanadate alone 
increased 125I-IGF-II binding; 1.6 + 0.2, 3.9 + 0.3 and 5.6 
+ 0.1 pg/105 cells for control, vanadate 0.5 mM (P  < 
0.01) and 4 mM (P <0.001), respectively (n=4) .  As 
shown in Fig. 3, vanadate did not, however, improve the 
impaired response to insulin following OA. Insulin sensi- 
tivity, measured as ECs0 for insulin-stimulated t25I-IGF-II 
binding, was not clearly affected by OA, but this was 
difficult to evaluate due to the blunted dose-response 
curve (Fig. 3). 
Addition of the MHC-I peptide (30 ~M) during the 
preincubation period clearly increased ~25I-IGF-II binding 
both in the presence or absence of insulin. This effect was 
also markedly reduced by concomitant or subsequent addi- 
tion of N6-mbcAMP (data not shown). 
3.2. Effects of PLC on 125I-IGF-H binding to intact cells, 
plasma membrane and solubilized receptors 
As seen in Fig. 4, PLC in a concentration-dependent 
manner markedly enhanced 125I-IGF-II binding to energy- 
depleted cells and ECs0 for this effect was 2.8 + 0.2 U/ml 
(n = 4). The maximal effect of PLC (25 U/ml)  on 125I- 
IGF-II binding was ~ 4-fold compared to control cells. 
However, at higher concentration of PLC (50 U/ml), 
125I-IGF-II binding declined to the control evel. Scatchard 
analysis demonstrated that the effect of PLC (5 U/ml) on 
125I-IGF-II binding was due to an increase in the number 
of binding sites by 2.5-fold (n = 3, P < 0.05) without any 
clear change in receptor affinity (Fig. 4, inset). 
Experiments with PLC were also performed with iso- 
lated PM as described in Section 2. PLC at the same 
concentrations a those used in intact cells, however, did 
not increase I:5I-IGF-II binding to PM nor was I:5I-IGF-II 
binding to receptors from solubilized PM affected by the 
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IGF-I I  binding was decreased compared to cells treated 
with insulin alone (Fig. 1). PLC (5 U /ml ) ,  however, 
increased ~25I-IGF-II binding to N6-mbcAMP-treated cells 
to a similar magnitude as in control cells (Fig. 5). PLC 
also reversed the N6-mbcAMP-induced ecrease of 125I- 
IGF-I I  binding at a low insulin concentration (10 /zU/ml)  
(n = 4, P < 0.05). In the presence of higher concentrations 
of insulin, PLC did not increase 125I-IGF-II binding and 
this was also true for cells treated with insulin plus N 6- 
mbcAMP (Fig. 5). 
To examine whether PLC induces an insulin signal we 
also performed control experiments with immunoblots with 
phosphotyrosine antibodies on cell lysates. However, PLC 
treatment (1 or 5 U /ml )  alone of cells did not alter 
tyrosine phosphorylation of insulin-regulated proteins in- 
cluding the insulin receptor/3-subunit (data not shown). 
PLC (U/ml) 
Fig. 4. Effects of PLC on cell surface 125I-IGF-II binding. Cells were 
pretreated with 2 mM KCN at 37°C for 5 rain. Binding of a25I-IGF-II (0.2 
ng/ml) was subseqently performed inthe presence of different concentra- 
tions of PLC at 24°C for 30 rain as described in Section 2. Data are 
means + S.E,M. of 4 separate experiments. (* P < 0.05, compared to 
binding in cells without PLC treatment). The inset in Fig. 4 shows a 
Scatchard plot. Cells were pretreated with 2 mM KCN at 37°C for 5 min 
and then incubated with 0.2 ng/ml n251-IGF-II at 24°C for 30 min 
together with different concentrations of unlabelled IGE-II in the presence 
(O) or absence ( • ) of 5 U/ml PLC. The results are from one representa- 
tive experiment repeated three times. 
addition of PLC at different concentrations (data not 
shown). 
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Fig. 5. Effects of PLC on 125I-IGF-II binding to insulin-stimulated c lls. 
Cells were preincubated with or without 4 mM Nr-mbcAMP (cAMP) at 
37°C for 5 min, then with the indicated concentrations of insulin for 
another 15 min. Following 2 mM KCN treatment for 5 rain, binding of 
12~I-IGF-II (0.2 ng/ml) was performed at24°C for 30 min in the absence 
or presence of 5 U/ml PLC. Cell-associated radioactivity was subse- 
qently determined. Data are means + S.E.M. of 3-8 separate experiments 
( * P < 0.05, compared to corresponding group without PLC treatment). 
4.  D iscuss ion  
Previous studies [1,6] showed that the stimulating effect 
of insulin as well as the counteracting effect of cAMP on 
cell-surface IGF-I I  binding are not fully accounted for by 
receptor translocation. In experiments using cell fractiona- 
tion, receptor distribution between the cell interior and the 
PM was not sufficient to explain the effects on IGF-II  
binding found in intact cells [1,6]. This suggests that 
additional mechanisms are involved in the regulation of 
cell surface IGF-I I  binding. In analogy with findings with 
respect to the glucose transporter GLUT 4 [14] and the 
insulin receptor [10,15,16], one possibility is the docking, 
fusion and/or  insertion at the PM, whereby the IGF-II 
receptor is functionally expressed at the cell surface. This 
would tentatively be promoted by insulin and impaired by 
cAMP. 
Both tyrosine and serine phosphorylation events are 
involved in the insulin signaling pathways [17-19]. In the 
present study both vanadate and okadaic acid, a tyrosine 
and a serine/threonine phosphatase inhibitor [18,20], re- 
spectively, exerted insulin-like effects on ~25I-IGF-II bind- 
ing. Even though OA alone displayed an insulin-like ac- 
tion, it exerted an opposing effect when added together 
with insulin. This suggests that serine/threonine phospho- 
rylation of key insulin-regulated proteins impairs insulin 
action. Since insulin responsiveness was attenuated by OA 
as well as Nr-mbcAMP, post-receptor steps appear to be 
involved. These may include insulin signaling proteins, 
such as the insulin receptor substrate-I (IRS-I) [20], but 
also the IGF-I I  receptor itself which may become serine 
phosphorylated [21,22]. 
The cAMP-analogue N6-mbcAMP inhibited both in- 
sulin responsiveness and sensitivity as was also previously 
shown [6,23]. Cyclic AMP can induce serine phosphoryla- 
tion of the insulin receptor leading to a decrease in tyro- 
sine kinase activity and, possibly, also to an incomplete 
functional expression of PM-associated insulin receptors at 
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the cell surface [9,16,24]. This may account for the insensi- 
tivity to insulin produced by cAMP treatment. Moreover, 
one cannot exclude the possibility that cAMP via serine 
phosphorylation f the IGF-II receptor itself [22] impairs 
its full insertion in the PM. The finding of a more pro- 
nounced inhibitory effect of cAMP when OA was also 
present supports the concept of a serine-phosphorylation 
step impairing the functional availability of IGF-II recep- 
tors at the cell surface. Further support for a PM mecha- 
nism for the inhibitory action of cAMP on IGF-II receptors 
was obtained with experiments with the MHC-I peptide 
fragment which effectively inhibits receptor internalization 
[25]. Even in the presence of this peptide, when IGF-II 
receptors are accumulated and 'locked' in the PM, N 6- 
mbcAMP produced a clear impairment of IGF-II binding. 
Vanadate was capable of restoring insulin sensitivity in 
cAMP-treated, but not insulin responsiveness in cAMP- or 
OA-treated cells. Tyrosine phosphorylation f key proteins 
in the insulin signaling pathway is critical for insulin 
action [17]. Possibly, the effect of vanadate is partly 
exerted at the level of the insulin-receptor, since it was 
previously shown at our laboratory that vanadate can 
enhance cell-surface insulin binding capacity, even in the 
presence of cAMP [10]. Taken together, these data suggest 
that in addition to translocation between the interior and 
the surface of the cell, also mechanisms in the PM regulate 
the functional insertion of IGF-II receptors. Tyrosine and 
serine phosphorylation appear to have opposite ffects in 
this regard. This is similar to what has recently been found 
concerning insulin receptor insertion in the PM (J.W. 
Eriksson et al., to be published). The PM-associated mech- 
anisms vis-a-vis the IGF-II receptor may involve either the 
conformation of the receptor, its insertion in the PM or 
both. 
The present work further suggests the idea of a critical 
insertion step in the PM, since PLC, which cleaves phos- 
pholipids at the cell surface [12], markedly increased 1251- 
IGF-II binding to rat fat cells. This was attributed to an 
increase in the number of binding sites without any change 
in receptor affinity suggesting uncovering of functionally 
cryptic receptors associated with the PM [12]. Additional 
experiments with IGF-II binding to solubilized PM argue 
against a direct effect of PLC on the affinity of the IGF-II 
receptor. Since the protocol used in the 125I-IGF-II binding 
experiments included cellular ATP depletion with KCN, 
possible PLC effects on insulin signaling and receptor 
translocation are very unlikely as was also shown with the 
phosphotyrosine immunoblots. Another possible error 
would be that PLC-induced cell leakage leads to ~25I-IGF-II 
binding to non-specific ell structures. However, this is 
unlikely, since non-specific binding of ~25I-IGF-II in PLC- 
treated cells was not consistently changed compared to 
control cells (data not shown). Taken together, a plausible 
interpretation of the PLC effect would be that unexposed 
and/or incompletely inserted IGF-II receptors are associ- 
ated with the PM. A similar effect of PLC has previously 
been demonstrated with respect o 'cryptic' insulin recep- 
tors in the PM [12]. 
The failure to demonstrate a PLC effect directly in the 
PM preparations may be explained by the possibility that 
unexposed and/or incompletely inserted IGF-II receptors 
associated with the PM in intact cells become fully in- 
serted uring the preparation of PM. Our recent data on the 
insulin receptor suggest such a possibility (J.W. Eriksson 
et al., to be published). 
An interesting finding is that PLC can reverse the 
impairment of IGF-II binding induced by N6-mbcAMP in 
cells stimulated with a low insulin concentration (10 
p~U/ml; see Fig. 5). This observation suggests that 
insulin-stimulated insertion of the IGF-II receptors in the 
PM is impaired by cAMP and this could be one of the 
mechanisms for cAMP-induced cellular insulin insensitiv- 
ity with respect to IGF-II binding. In contrast, PLC 
markedly reduced IGF-II binding in cells pretreated with 
high insulin concentrations both in the presence and ab- 
sence of N6-mbcAMP and the reasons for this are not 
clear. Possibly, high insulin concentrations lead to full 
IGF-II receptor insertion even in the presence of cAMP. In 
contrast, insulin binding is enhanced by PLC also when 
cells have been stimulated with high concentrations of
insulin (J.W. Eriksson et al., to be published) and there 
may possibly be cryptic insulin but not IGF-II receptors 
after full insulin stimulation. Moreover, the IGF-II receptor 
is a monomeric, single-stranded peptide with a large extra- 
cellular domain [2,26], and it may be more fragile than the 
tetrameric nsulin receptor and it might perhaps be released 
from the PM upon PLC treatment when it has already been 
fully inserted in response to a high insulin concentration. 
Effects of cAMP, similar to those presently reported, 
have also been suggested with respect o PM fusion and 
cell-surface xposure of yet another insulin-regulated pro- 
tein, the glucose transporter GLUT 4 [14,27]. Therefore, 
the impairment of exposure of insulin-regulated proteins 
resulting in a reduced availability at the cell surface may 
be a common perturbation i cAMP-induced insulin resis- 
tance. Moreover, specific tyrosine and serine phosphoryla- 
tion events, e.g., of docking proteins or, to some extent, of 
the receptors and transporters per se, may directly regulate 
the fusion and insertion processes of all these insulin-re- 
sponsive proteins - the insulin and IGF-II receptors and 
GLUT 4 - in the PM as also suggested by previous work 
[28-30]. 
In conclusion, this study suggests that IGF-II receptors, 
similar to insulin receptors and glucose transporters, can be 
associated with the PM, without being functionally avail- 
able at the cell surface. The proportion of such cryptic 
receptors may increase in insulin-resistant states, e.g., ele- 
vated cAMP levels, probably through mechanisms involv- 
ing serine phosphorylation. If this is a general phe- 
nomenon, as current data suggest, incomplete receptor 
insertion may be of importance for the impaired sensitivity 
and responsiveness to insulin in these states. 
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